Immune checkpoint inhibitor-induced immune-related adverse events oft he peripheral nervous system – from mechanisms towards prediction and targeted treatment

Immunotherapies have revolutionized cancer treatment. However, one of 15 patients develops severe neurological adverse events, for which targeted treatment options and predictive markers are missing. Within the research project, the scientists establish the first animal model of neurological immune-related adverse events (irAE-n) and analyze patient-derived immune cells driving irAE-n, to identify the underlying disease mechanisms and to test new therapeutic approaches. In addition, they will investigate, whether genetic markers or specific antibodies in the peripheral blood may be used to predict neurological adverse events. The overall goal is to prevent neurological side effects and to thereby improve the quality of life of patients with cancer.